Literature DB >> 33961787

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.

Giovanni Targher1, Herbert Tilg2, Christopher D Byrne3.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a public health problem worldwide. This narrative Review provides an overview of the current literature to support the notion that NAFLD is a multisystem disease. Convincing evidence shows a strong association between NAFLD and the risk of developing multiple extrahepatic complications such as type 2 diabetes, cardiovascular disease (ie, the predominant cause of mortality in people with NAFLD), chronic kidney disease, and some types of extrahepatic malignancies. The magnitude of this risk parallels the severity of NAFLD (especially the stage of liver fibrosis). There are probably multiple underlying mechanisms by which NAFLD might increase the risk of cardiovascular disease, type 2 diabetes, and extrahepatic complications. Addressing the growing burden of NAFLD will require setting up a multidisciplinary working group and framework to progress and embrace novel collaborative ways of working to deliver holistic, person-centred care and management of people with NAFLD.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 33961787     DOI: 10.1016/S2468-1253(21)00020-0

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  23 in total

1.  Long-term outcomes in patients with non-alcoholic fatty liver disease: further evidence that a multidisciplinary and patient-centred approach to treatment is needed.

Authors:  Giovanni Targher
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

Review 2.  Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.

Authors:  Amedeo Lonardo; Alessandro Mantovani; Salvatore Petta; Amedeo Carraro; Christopher D Byrne; Giovanni Targher
Journal:  Nat Rev Endocrinol       Date:  2022-07-15       Impact factor: 47.564

Review 3.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

4.  A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population.

Authors:  Qingling Wang; Da Zhou; Mingjie Wang; Mingyu Zhu; Peizhan Chen; Hu Li; Meng Lu; Xinxin Zhang; Xizhong Shen; Taotao Liu; Li Chen
Journal:  Front Med (Lausanne)       Date:  2022-06-20

5.  Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease.

Authors:  Lei Miao; Li Yang; Li-Sha Guo; Qiang-Qiang Shi; Teng-Fei Zhou; Yang Chen; Huai Zhang; Hui Cai; Zhi-Wei Xu; Shuan-Ying Yang; Hai Lin; Zhe Cheng; Ming-Yang Zhu; Xu Nan; Shuai Huang; Ya-Wen Zheng; Giovanni Targher; Christopher D Byrne; Yu-Ping Li; Ming-Hua Zheng; Cheng-Shui Chen
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

6.  Intermittent Hypoxia Rewires the Liver Transcriptome and Fires up Fatty Acids Usage for Mitochondrial Respiration.

Authors:  Jonathan Gaucher; Guillaume Vial; Emilie Montellier; Maëlle Guellerin; Sophie Bouyon; Emeline Lemarie; Véronique Pelloux; Anne Bertrand; Karin Pernet-Gallay; Frederic Lamarche; Anne-Laure Borel; Claire Arnaud; Elise Belaidi; Karine Clément; Diane Godin Ribuot; Judith Aron-Wisnewsky; Jean-Louis Pépin
Journal:  Front Med (Lausanne)       Date:  2022-02-18

7.  Editorial commentary on Indian Journal of Gastroenterology-July-August 2021.

Authors:  Jimmy K Limdi
Journal:  Indian J Gastroenterol       Date:  2021-08

8.  Perception of Non-Alcoholic Fatty Liver Disease: Real-Life Experience From Pakistan.

Authors:  Nazish Butt; Muhammad Ali Khan; Lajpat Rai; Riaz Hussain Channa; Hanisha Khemani; Amanullah Abbasi
Journal:  Cureus       Date:  2021-06-29

9.  Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.

Authors:  Yoshitaka Hashimoto; Masahide Hamaguchi; Takuro Okamura; Naoko Nakanishi; Akihiro Obora; Takao Kojima; Michiaki Fukui
Journal:  J Diabetes Investig       Date:  2021-10-12       Impact factor: 4.232

10.  Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study.

Authors:  Byoungduck Han; Gyu Bae Lee; Sun Young Yim; Kyung-Hwan Cho; Koh Eun Shin; Jung-Hwan Kim; Yong-Gyu Park; Kyung-Do Han; Yang-Hyun Kim
Journal:  Diagnostics (Basel)       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.